Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@jax.org
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|
NRAS Q61L | melanoma | predicted - sensitive | NST-628 | Preclinical - Cell line xenograft | Actionable | In a preclinical study, NST-628 induced tumor regression in a melanoma cell line xenograft model harboring NRAS Q61L (Mol Cancer Ther (2023) 22 (12_Supplement): A088). | detail... |
PubMed Id | Reference Title | Details |
---|---|---|
Abstract A088: NST-628 is a potent, best-in-class MAPK pathway molecular glue that inhibits RAS- and RAF-driven cancers | Full reference... |